Current Assets
Accounts Receivable
Gilead Sciences Accounts Receivable decreased by 18.0% to $4.91B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 11.2%, from $4.42B to $4.91B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows relatively stable performance with a 0.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
An increase relative to sales may signal slowing collections or credit risk, while a decrease suggests efficient cash conversion.
Detailed definition
The total amount of credit extended to customers and channel partners for products sold or services rendered, minus an a...
Peer comparison
Typically scales with revenue growth; however, companies with strong direct-to-consumer channels may have lower receivables relative to those relying on third-party distributors.
Metric ID:
accounts_receivable_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.91B | $5.28B | $4.49B | $4.56B | $4.90B | $5.01B | $4.78B | $4.93B | $5.05B | $5.59B | $4.66B | $5.52B | $5.49B | $5.46B | $4.42B | $5.26B | $5.62B | $5.99B | $4.91B |
| QoQ Change | — | +7.7% | -15.0% | +1.5% | +7.5% | +2.1% | -4.6% | +3.3% | +2.4% | +10.6% | -16.6% | +18.4% | -0.6% | -0.4% | -19.1% | +18.9% | +7.0% | +6.6% | -18.0% |
| YoY Change | — | — | — | — | -0.1% | -5.3% | +6.3% | +8.2% | +3.0% | +11.6% | -2.4% | +11.9% | +8.7% | -2.2% | -5.2% | -4.8% | +2.5% | +9.7% | +11.2% |
Range$4.42B – $5.99B
CAGR+0.0%
Avg YoY Growth+3.5%
Median YoY Growth+3.0%
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's accounts receivable?
- Gilead Sciences (GILD) reported accounts receivable of $4.91B in Q4 2025.
- How has Gilead Sciences's accounts receivable changed year-over-year?
- Gilead Sciences's accounts receivable increased by 11.2% year-over-year, from $4.42B to $4.91B.
- What is the long-term trend for Gilead Sciences's accounts receivable?
- Over 5 years (2020 to 2025), Gilead Sciences's accounts receivable has grown at a 0.1% compound annual growth rate (CAGR), from $4.89B to $4.91B.
- What does accounts receivable mean?
- The amount of money customers owe the company for products they have already received.